Pfizer: COVID-19 May Never End

Nov. 29, 2022 8:53 PM ETPfizer Inc. (PFE)ABBV, BMY, BMYMP, GLAXF, GSK, JNJ, LLY, MRK, NVS, NVSEF, REGN, RHHBF, RHHBY, RHHVF, SPY, VIR172 Comments
Nathan Aisenstadt profile picture
Nathan Aisenstadt
2.83K Followers

Summary

  • Pfizer's net income was $8,609 million in Q3 2022, up 5.7% year-on-year.
  • The number of Pfizer product candidates continues to grow at a significant pace due to the continued high sales of Paxlovid.
  • Sales of Pfizer's COVID-19 vaccine have plummeted in recent quarters due to declining public interest in getting vaccinated.
  • The company's total debt was $36,999 million in Q3 2022, down about $3.5 billion from the previous quarter.
  • A worsening COVID-19 situation in China and a significant decrease in the effectiveness of monoclonal antibodies against new variants of the virus will bring Pfizer billions of dollars in profits in the coming quarters.

Космический корабль взлетает. Космический челнок с дымом и взрывом взлетает в космос на фоне заката с полной луной.

vadimrysev/iStock via Getty Images

On November 1, 2022, Pfizer (NYSE:PFE) released its Q3 2022 financial report, which showed that the business strategy implemented by the company's management is beginning to bear fruit. Despite the continued downward trend in sales of

Source: Author's elaboration, based on Investing.com

Source: Author's elaboration, based on Investing.com

Source: Author's elaboration, based on quarterly securities report

Source: Author's elaboration, based on quarterly securities report

Source: Author's elaboration, based on Seeking Alpha

Source: Author's elaboration, based on Seeking Alpha

Source: Author's elaboration, based on quarterly securities report

Source: Author's elaboration, based on quarterly securities report

ImageSource: Twitter post

Source: Twitter post

Source: Author's elaboration, based on quarterly securities reports

Source: Author's elaboration, based on quarterly securities reports

Source: Author's elaboration, based on HHS

Source: Author's elaboration, based on HHS

Source: Information provided by Google

Source: Information provided by Google

This article was written by

Nathan Aisenstadt profile picture
2.83K Followers
I am an independent research analyst focused on finding undervalued assets with above-average growth rates and developments that can dramatically improve the company's financial position. When investing, I use medium-term and long-term trading strategies that take into account psychological and behavioral variables and are able to mitigate the risks associated with macroeconomic and geopolitical instability.The main sectors of analysis are industrials, materials, crypto, and healthcare.When analyzing assets in the healthcare sector, in addition to examining their financial position, I delve into the safety and efficacy data of the company's product candidates from preclinical and clinical studies, allowing me to evaluate their commercial prospects. While the education received at the Hebrew University of Jerusalem contributes to a comprehensive and detailed analysis of biotechnological and physicochemical processes used in the production of goods in the agricultural, oil and gas, and chemical industries. As a result, it allows me to find the most promising assets in a rapidly changing market and publish meaningful articles on Seeking Alpha.My e-mail for any questions and suggestions: aisenathan@gmail.com

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sell securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.

Recommended For You

Comments (172)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.